Palatin Technologies patents expiration
1. Vyleesi (autoinjector) patents expiration
VYLEESI (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6794489 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| US11590209 | PALATIN TECHNOLOGIES | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 2023-06-22
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd); Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecti...
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
VYLEESI (AUTOINJECTOR) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic